News Releases

Date Title and Summary View
Nov 13, 2000
Johnson & Johnson to Participate In Merrill Lynch Medical Technology Fundamentals Conference
Johnson & Johnson to Participate In Merrill Lynch Medical Technology Fundamentals Conference NEW BRUNSWICK, N.J., Nov. 13 -- Johnson & Johnson today announced that it will participate in the Merrill Lynch Medical Technology Fundamentals Conference at the Metropolitan Club in New York City on
Nov 06, 2000
Cordis Receives FDA Approval for New Product To Treat Patients In-Stent Restenosis
Cordis Receives FDA Approval for New Product To Treat Patients In-Stent Restenosis MIAMI, Nov. 6 -- Cordis Corporation -- the Johnson & Johnson company that pioneered the cardiovascular stent -- received U.S. Food and Drug Administration approval on Friday to market the CHECKMATE(TM) System, an
Nov 06, 2000
ADVISORY/FDA Approves Marketing Of Checkmate System for Coronary Artery Disease
ADVISORY/FDA Approves Marketing Of Checkmate System for Coronary Artery Disease Until now, no development has been able to overcome the obstacle of recurrent blockages, in treated coronary artery lesions. Cordis Corporation -- the Johnson & Johnson company that pioneered the cardiovascular stent --
Oct 17, 2000
Johnson & Johnson To Distribute Over One Million Free Copies of a Newsweek Magazine Special on Early Childhood Development
Johnson & Johnson To Distribute Over One Million Free Copies of a Newsweek Magazine Special on Early Childhood Development NEW BRUNSWICK, N.J., Oct. 17 --Johnson & Johnson brands are the exclusive advertisers in Your Child: From Birth to Three, a special issue of Newsweek magazine that arrives
Oct 17, 2000
Johnson & Johnson 2000 Third Quarter EPS Rose 14.1%; Sales Increased 4.6%; Net Earnings Rose 13.8
Johnson & Johnson 2000 Third Quarter EPS Rose 14.1%; Sales Increased 4.6%; Net Earnings Rose 13.8 NEW BRUNSWICK, N.J., Oct. 17 -- Johnson & Johnson (NYSE: JNJ) today announced sales of $7.2 billion and net earnings of $1.3 billion for the third quarter of 2000, increases of 4.6% and 13.8%,
Oct 16, 2000
Johnson & Johnson-Merck Receives FDA Approval for Pepcid Complete, A Unique New Way To Treat Heartburn
Johnson & Johnson-Merck Receives FDA Approval for Pepcid Complete, A Unique New Way To Treat Heartburn FT. WASHINGTON, Pa., Oct. 16 -- The U.S. Food and Drug Administration today approved for marketing Pepcid ® Complete, a new way to treat heartburn and acid indigestion for the approximate 100
Sep 28, 2000
ADVISORY/The Women's Museum: An Institute for the Future Opens in Dallas
ADVISORY/The Women's Museum: An Institute for the Future Opens in Dallas ADVISORY...for Thursday NOTE TO EDITORS: Multimedia Assets Available With This Story Include Video, Corporate Logos, Full Text Release --Sept. 28, 2000--The Women's Museum: An Institute for the Future, a unique national
Sep 26, 2000
ADVISORY/Pharmacists Across America Urge Consumers To 'Review, Remove, And Restock'
ADVISORY/Pharmacists Across America Urge Consumers To 'Review, Remove, And Restock' --In preparation for the first cold and flu season of the new millennium, pharmacists across the country are participating in the Medicine Cabinet Safety campaign, an educational program designed to inform consumers
Sep 26, 2000
FDA Approves Cordis Trufill® n-BCA Liquid Embolic Treatment System For Cerebral 'AVMs'
FDA Approves Cordis Trufill ® n-BCA Liquid Embolic Treatment System For Cerebral 'AVMs' MIAMI, Sept. 26 -- Cordis Neurovascular today reported U.S. Food and Drug Administration (FDA) approval of the Company's new TRUFILL ® n-BCA* Liquid Embolic System for presurgical embolization of cerebral
Jul 18, 2000
Johnson & Johnson 2000 Second Quarter EPS Rose 14.6% Sales Increased 7.7% Net Earnings Rose 14.3
Johnson & Johnson 2000 Second Quarter EPS Rose 14.6% Sales Increased 7.7% Net Earnings Rose 14.3 NEW BRUNSWICK, N.J., July 18 -- Johnson & Johnson (NYSE: JNJ) today announced record sales of $7.5 billion and record net earnings of $1.3 billion for the second quarter of 2000, increases of 7.7% and
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.